drugset / Trial / NCT05405621
Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009
Non-randomizedSequentialOpen-labelTreatment
Summary
Primary objectives: * To evaluate the safety and tolerability of BAT8009 in patients with advanced solid tumours. * To determine the maximum tolerated dose (MTD) and recommended dose for Phase 2 (RP2D).
Timeline
- Start
- 2022-08-02
- Primary completion
- 2023-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT8009 | Unknown | 0.6 mg/kg | Intravenous |
| Subject | BAT8009 | Unknown | 1.2 mg/kg | Intravenous |
| Subject | BAT8009 | Unknown | 2.4 mg/kg | Intravenous |
| Subject | BAT8009 | Unknown | 3.6 mg/kg | Intravenous |
| Subject | BAT8009 | Unknown | 4.8 mg/kg | Intravenous |
| Subject | BAT8009 | Unknown | 6 mg/kg | Intravenous |
| Subject | BAT8009 | Unknown | 7.2 mg/kg | Intravenous |
| Subject | BAT8009 | Unknown | 8.4 mg/kg | Intravenous |
Indications
No indication recorded.